The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level-Can it rule out clinically significant prostate cancer?

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 45.e17-45.e22

  Abd Alazeez, Mohamed ^a,b   Ahmed, Hashim U ^a,c   Arya, Manit ^a,d   Charman, Susan C ^e   Anastasiadis, Eleni ^f   Freeman, Alex ^a   Emberton, Mark ^a,c   Kirkham, Alex ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Fayoum University   (Egypt)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

Clinically significant disease; Multiparametric MRI; Negative biopsy; Template prostate mapping

Indexed keywords

GADOTERATE MEGLUMINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

CLINICALLY SIGNIFICANT DISEASE; MULTIPARAMETRIC MRI; NEGATIVE BIOPSY; TEMPLATE PROSTATE MAPPING;

ADULT; AGED; BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 84890799470     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.06.007     Document Type: Article

References (21)

1. Djavan B., Ravery V., Zlotta A., et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?. J Urol 2001, 166:1679-1683.
2. McNeal J.E., Redwine E.A., Freiha F.S., Stamey T.A. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988, 12:897-906.
3. Merrick G. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007, 52:715-724.
4. Park B.K., Lee H.M., Kim C.K., Choi H.Y., Park J.W. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Invest Radiol 2008, 43:789-793.
5. Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2010, 183:520-527.
6. Puech P., Potiron E., Lemaitre L., et al. Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009, 74:1094-1099.
7. Villers A., Puech P., Mouton D., Leroy X., Ballereau C., Lemaitre L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006, 176:2432-2437.
8. Mabjeesh N.J., Lidawi G., Chen J., German L., Matzkin H. High detection rate of significant prostate tumours in anterior zones using transperineal ultrasound-guided template saturation biopsy. BJU Int 2012, 110:993-997.
9. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757.
10. Barzell W.E., Melamed M.R. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate-a 4-year experience. Urology 2007, 70:27-35.
11. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1 c) prostate cancer. J Am Med Assoc 1994, 271:368-374.
12. Bastian P.J., Mangold L.A., Epstein J.I., Partin A.W. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004, 101:2001-2005.
13. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
14. Karram S., Trock B.J., Netto G.J., Epstein J.I. Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol 2011, 35:1351-1355.
15. Kirkham A.P., Emberton M., Allen C. How good is MRI at detecting and characterising cancer within the prostate?. Eur Urol 2006, 50:1163-1174. [discussion 75].
16. Merrick G.S., Gutman S., Andreini H., et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007, 52:715-723.
17. Portalez D., Mozer P., Cornud F., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012, 62:986-996.
18. Franiel T., Stephan C., Erbersdobler A., et al. Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding-multiparametric MR imaging for detection and biopsy planning. Radiology 2011, 259:162-172.
19. Arumainayagam N., Ahmed H.U., Moore C.M., et al. Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology 2013, 268:761-769.
20. Bittner N., Merrick G.S., Butler W.M., Bennett A., Galbreath R.W. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol 2013, 190:509-514.
21. Ahmed H.U., Hu Y., Carter T., et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011, 186:458-464.